Press-release for stocks for LLY

Prices are updated after-hours

Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet
Published: 2021-03-05 (Crawled : 12:09) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M

| 264.68% | O: 0.24% H: 3.31% C: 2.94%
phase 1 phase 3 phase 2 lancet

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial
Published: 2021-03-03 (Crawled : 12:09) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M

| 258.25% | O: -0.38% H: 0.46% C: -0.67%
INCY | $51.62 -0.58% -0.58% 2.5M

| -33.91% | O: -0.3% H: 0.33% C: -2.94%
growth phase 3 trial baricitinib hair regrowth

78%

22%

MTTR | News M | $4.6 164.37% 62.17% 28M

AGBA | $2.94 135.2% 57.48% 66M

EDBL | News | $6.46 71.81% 41.8% 2M

MTC | $2.25 44.23% 30.67% 6M

OPRT | News | $3.175 41.11% 29.13% 12M

SHIM | $3.05 35.56% 26.23% 1.1M

HKIT | $1.345 31.86% 24.16% 390K

ABVC | $1.36 30.77% 23.53% 7.4M

OST | $0.512 28.0% 21.88% 290K

POET | $1.59 27.2% 21.38% 4.2M

Save your searches and get alerts when important news are released.